Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

Next Previous
X
Search
Trial Profile

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide (Primary)
  • Indications Adenocarcinoma; Glucagonoma; Insulinoma; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
    • 14 Nov 2023 Planned End Date changed from 1 Jul 2023 to 1 Jan 2024.
    • 19 Oct 2022 Results assessing efficacy and safety of temozolomide versus temozolomide in combination with capecitabine in patients with advanced pancreatic neuroendocrine tumors, published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top